首页> 美国卫生研究院文献>Molecular Pharmacology >The Tetrahydroisoquinoline Derivative SB269652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors
【2h】

The Tetrahydroisoquinoline Derivative SB269652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors

机译:四氢异喹啉衍生物SB269652是一种变构物 多巴胺D3和D2受体的拮抗剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In view of the therapeutic importance of dopamine D3 and D2 receptors, there remains considerable interest in novel ligands. Herein, we show that the tetrahydroisoquinoline 1H-indole-2-carboxylic acid {4-[2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-amide (SB269,652) behaves as an atypical, allosteric antagonist at D3 and D2 receptors. Accordingly, SB269,652 potently (low nanomolar range) abolished specific binding of [3H]nemanopride and [3H]spiperone to Chinese hamster ovary-transfected D3 receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D3 receptor-mediated activation of Gαi3 and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gαi3. SB269,652 (up to 10 μM) only weakly and partially (by approximately 20–30%) inhibited radioligand binding to D2 receptors. Likewise, SB269,652 only submaximally suppressed D2 receptor-mediated stimulation of Gαi3 and Gαqi5 (detected with the aequorin assay) and phosphorylation of ERK1/2 and Akt. Furthermore, SB269,652 only partially (35%) inhibited the dopamine-induced recruitment of β-arrestin2 to D2 receptors. Finally, Schild analysis using Gαi3 assays, and studies of radioligand association and dissociation kinetics, supported allosteric actions of SB269,652 at D3 and D2 receptors.
机译:考虑到多巴胺D3和D2受体的治疗重要性,对新型配体仍然有相当大的兴趣。在此,我们表明四氢异喹啉1H-吲哚-2-羧酸{4- [2-(氰基-3,4-二氢-1H-异喹啉-2-基)-乙基]-环己基}-酰胺(SB269,652 )在D3和D2受体上表现为非典型的变构拮抗剂。因此,SB269,652有效地(低纳摩尔范围)取消了放射性配体与[ 3 H] nemanopride和[ 3 H]烯哌隆与中国仓鼠卵巢转染的D3受体的特异性结合。分别以0.2和0.5 nM使用。但是,即使在高浓度(5μM)下,当以高10倍的浓度使用这些放射性配体时,SB269,652也只能最大程度地抑制这些放射性配体的特异性结合。以此类推,尽管SB269,652有效地阻断了D3受体介导的Gαi3的激活和细胞外信号调节激酶(ERK)1/2的磷酸化,但是当多巴胺的浓度增加了10倍时,从1μM增至10μM, SB269,652仅最大程度地抑制了多巴胺诱导的Gαi3刺激。 SB269,652(最大10μM)仅弱而部分(大约20–30%) 抑制放射性配体与D2受体的结合。同样,仅SB269,652 D2受体介导的亚最大抑制 Gαi3和Gαqi5(通过 水母发光蛋白测定)和ERK1 / 2和Akt的磷酸化。此外,仅SB269,652 (35%)部分抑制多巴胺诱导的β-arrestin2募集 D2受体。最后,使用Schild分析 Gαi3测定以及放射性配体缔合和 解离动力学,支持SB269,652在D3和 D2受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号